Lite Strategy, Inc. Deferred Revenue Recognized
Lite Strategy, Inc. (LITS) reported Deferred Revenue Recognized of -$317.00 thousand for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-09.
Discontinued › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2023-11-09
- Lite Strategy, Inc. contract with customer, liability, revenue recognized for the quarter ending 2023-09-30 was -$317.00K.
- Lite Strategy, Inc. contract with customer, liability, revenue recognized for the quarter ending 2022-09-30 was -$971.00K, a 332.85% decline year-over-year.
- Lite Strategy, Inc. contract with customer, liability, revenue recognized for the quarter ending 2021-09-30 was $417.00K.
- Lite Strategy, Inc. contract with customer, liability, revenue recognized for the quarter ending 2020-09-30 was -$1.72M.
- Lite Strategy, Inc. contract with customer, liability, revenue recognized for fiscal 2022 was -$3.78M.
- Lite Strategy, Inc. contract with customer, liability, revenue recognized for fiscal 2021 was -$4.80M.
- Lite Strategy, Inc. contract with customer, liability, revenue recognized for fiscal 2020 was -$25.23M.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 6 month as first filed | Contract with Customer, Liability, Revenue Recognized 9 month | Contract with Customer, Liability, Revenue Recognized 12 month |
|---|---|---|---|---|---|
| 2023-09-30 | -$317.00K 10-Q · filed 2023-11-09 | ||||
| 2023-06-30 | -$5.41M 10-Q · filed 2023-11-09 | ||||
| 2023-03-31 | -$4.14M 10-Q · filed 2023-05-11 | ||||
| 2022-12-31 | -$2.83M 10-Q · filed 2023-02-09 | ||||
| 2022-09-30 | -$971.00K 10-Q · filed 2022-11-14 | ||||
| 2022-06-30 | -$3.78M 10-K · filed 2023-09-26 | ||||
| 2022-03-31 | -$2.51M 10-Q · filed 2023-05-11 | ||||
| 2021-12-31 | -$1.26M 10-Q · filed 2023-02-09 | $1.26M 10-Q/A · filed 2022-05-23 | |||
| 2021-09-30 | $417.00K 10-Q · filed 2022-11-14 | ||||
| 2021-06-30 | -$4.80M 10-K · filed 2022-09-08 | ||||
| 2021-03-31 | -$4.91M 10-Q · filed 2022-05-23 | ||||
| 2020-12-31 | $4.26M 10-Q/A · filed 2022-05-23 | ||||
| 2020-09-30 | -$1.72M 10-Q/A · filed 2022-05-23 | ||||
| 2020-06-30 | -$25.23M 10-K/A · filed 2022-05-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |